Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 24,441 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,441 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $3.34, for a total transaction of $81,632.94. Following the transaction, the chief executive officer directly owned 5,962,502 shares in the company, valued at $19,914,756.68. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Sight Sciences Trading Down 0.6%

Sight Sciences stock opened at $3.29 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 10.01 and a quick ratio of 9.49. The company has a market capitalization of $172.30 million, a price-to-earnings ratio of -3.43 and a beta of 2.41. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $6.29. The company’s fifty day moving average price is $3.74 and its two-hundred day moving average price is $3.47.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Thursday, August 7th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The firm had revenue of $19.56 million for the quarter, compared to the consensus estimate of $18.18 million. Sight Sciences had a negative net margin of 64.23% and a negative return on equity of 59.38%. Sight Sciences has set its FY 2025 guidance at EPS. On average, analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds have recently made changes to their positions in SGHT. CWM LLC lifted its stake in shares of Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after buying an additional 3,137 shares during the period. ProShare Advisors LLC bought a new stake in shares of Sight Sciences in the fourth quarter valued at about $36,000. Tower Research Capital LLC TRC lifted its stake in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after buying an additional 2,875 shares during the period. Bank of Montreal Can bought a new stake in shares of Sight Sciences in the second quarter valued at about $49,000. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in shares of Sight Sciences by 38.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock valued at $66,000 after buying an additional 4,453 shares during the period. Institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley increased their target price on shares of Sight Sciences from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Thursday, August 28th. Lake Street Capital raised Sight Sciences from a “hold” rating to a “buy” rating and raised their price target for the company from $3.00 to $5.00 in a research report on Friday, August 8th. Citigroup raised their price target on Sight Sciences from $3.60 to $4.50 and gave the company a “neutral” rating in a research report on Thursday, August 21st. Finally, Wall Street Zen raised Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.42.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.